Abstract
Fenofibrate is a medication derived from fibric acid that is used to treat severe cases of high triglyceride levels and a combination of abnormal lipid levels in individuals who have not shown improvement with nonpharmacological treatments. As part of this research, novel classes of Fenofibrate derivatives were synthesized and evaluated in vitro as anticancer and antioxidant agents. Spectroscopic techniques, including infrared, NMR and elemental analysis, were used to validate their structures conclusively. all products were screened in vitro against cell lines MDA-MB-231. The cytotoxicity assay results revealed that derivatives 5b and 5c exhibited good inhibition for MDA-MB-231. The IC50 values for derivatives 5b and 5c were 79.09 and 128.10 µg/m, respectively. A molecular docking study of the synthetic compounds confirmed the cytotoxicity test results. In addition, the DPPH investigation revealed good antioxidant activity for derivatives 5c and 5e with inhibition percentages of 93.85 and 92.31%, respectively, compared to ascorbic acid.